Skip to main content

Table 5 Multivariate analyses (cox regression) of relapse-free survival and overall survival a

From: Human BDH2, an anti-apoptosis factor, is a novel poor prognostic factor for de novo cytogenetically normal acute myeloid leukemia

Variables

Relapse-free survival

Overall survival

 

95% CI

  

95% CI

 

HR

Lower

Upper

P

HR

Lower

Upper

P

Whole cohort (n = 86)

        

Ageb

3.083

0.184

51.762

0.434

3.252

1.322

8.002

0.010*

NPM1 c

0.087

0.012

0.604

0.014*

0.392

0.128

1.195

0.100

FLT3- ITDd

21.079

1.427

311.302

0.026*

4.532

1.395

14.723

0.012*

FLT3- TKD

19.630

1.539

250.445

0.022*

1.801

0.184

17.603

0.613

CEBPA e

0.408

0.144

1.154

0.091

0.398

0.147

1.080

0.070

IDH1 c

0.448

0.039

5.167

0.520

0.648

0.128

3.268

0.599

IDH2 c

0.583

0.025

13.640

0.737

0.254

0.036

1.781

0.168

DNMT3A c

0.292

0.041

2.098

0.221

0.731

0.158

3.380

0.689

MLL c

31.310

0.729

1344.29

0.073

1.040

0.215

5.020

0.961

MN1

1.391

1.027

1.883

0.033*

1.195

1.025

1.394

0.023*

ERG

5.799

0.548

61.325

0.144

2.545

0.993

6.520

0.052

miR-181a

0.824

0.598

1.135

0.236

0.860

0.692

1.069

0.174

miR-3151

1.183

0.750

1.867

0.469

1.285

0.884

1.866

0.189

BDH2 f

2.035

0.472

8.782

0.341

2.547

1.094

6.685

0.050*

  1. Abbreviations: HR indicates Hazard ratio; CI, confidence interval.
  2. aOnly patients with intensive induction chemotherapy enrolled.
  3. bAge > 60 relative to Age ≤ 60 (the reference).
  4. cNPM1mut versus NPM1wild type; ID H1mut versus IDH1wild type; IDH2mut versus IDH2wild type; DNMT3Amut versus DNMT3Awild type ; MLLmut versus MLLwild.
  5. dFLT3- ITDmut versus FLT3- ITDneg.
  6. eCEBPAdouble-mutation versus CEBPAsingle mutation versus CEBPAno mutation.
  7. fBDH2high relative to BDH2low group.
  8. *Statistically significant (P < 0.05).
Back to article page

Journal of Biomedical Science

ISSN: 1423-0127